title: Low-dose long-term oral idarubicin in maintenance treatment of elderly acute myeloid leukemia.
abstract: OBJECTIVE
  Low-dose long-term oral IDA may play a role in maintainance treatment of elderly patients with AML; in fact, continuous exposure to IDA and IDAol could be efficacious in the disease control possibly inducing cell-differentiation and/or apoptosis.
  
  
  METHODS
  We enrolled 25 previous responder patients in standard induction therapy to receive maintenance oral IDA 5 mg daily on days 1-14 at 2-week intervals for at least 6 months. We also evaluated the cell-cycle and apoptosis in leukemic cells from patients after IDA administration and, as a control, from HL60 lines exposed to IDA and IDAol in vitro.
  
  
  RESULTS
  Long-term long-dose IDA was well-tolerated. Neutrophil and platelet count never below under 1 x 10(9)/L and 50 x 10(9)/L respectively in CR patients, and no infectious complications were encountered. Non-hematological toxicity was also acceptable: easily controlled nausea and vomiting, non-recorded diarrhea or mucositis were reported. The convenience of oral administration contributed to excellent compliance. DNA analysis performed in vivo after IDA and IDAol exposure showed an increase of G2/M cell frequencies and evidence of sub-G1 peak.
  
  
  CONCLUSIONS
  In conclusion, long-term low doses of oral IDA would appear valuable as a maintenance regimen for elderly patients. Our results seem to confirm the preliminary hypothesis that IDA + IDAol induce an increase of apoptosis in leukemic cells.
authors.affiliation: Cattedra Divisione di Ematologia con Trapianto di Midollo, Università di Palermo, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Musso
authors.forename: F
authors.initials: F
authors.lastname: Porretto
authors.forename: A
authors.initials: A
authors.lastname: Crescimanno
authors.forename: F
authors.initials: F
authors.lastname: Bondì
authors.forename: V
authors.initials: V
authors.lastname: Polizzi
authors.forename: R
authors.initials: R
authors.lastname: Scalone
authors.forename: M
authors.initials: M
authors.lastname: Tolomeo
authors.forename: G
authors.initials: G
authors.lastname: Mariani
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000627:therapeutic use*; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D000903:Antibiotics, Antineoplastic; D015255:Idarubicin